Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
Your view on EW
Overview
What the company does, where it operates, and who runs it.
About Edwards Lifesciences Corporation
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Bernard J. Zovighian
- Headquarters
- One Edwards Way, Irvine, CA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Bernard J. Zovighian
- Headquarters
- One Edwards Way, Irvine, CA, US
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally.
It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy.
In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation.
Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure.
The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Edwards Lifesciences Corporation from FRC's valuation model, read against the market price. EW last traded at $107.11, 60.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Edwards Lifesciences Corporation. Starting points for Edwards Lifesciences Corporation: P/E 60.2, EPS $1.77, beta 0.83 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Edwards Lifesciences Corporation. Edwards Lifesciences Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Edwards Lifesciences Corporation. Trailing twelve-month EPS for Edwards Lifesciences Corporation stands at $1.77. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$105.13
average of 15 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy15
- Hold3
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.66 | $0.84 | $3.02 | $3.41 |
| Low estimate | $0.64 | $0.79 | $3.01 | $3.32 |
| High estimate | $0.74 | $0.86 | $3.06 | $3.49 |
| No. of analysts | 16 | 12 | 17 | 17 |
| Year-ago EPS | $0.58 | $0.78 | $1.83 | — |
| Growth | +14.3% | +8.3% | +64.9% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.71B | $1.80B | $6.81B | $7.49B |
| Low estimate | $1.70B | $1.76B | $6.73B | $7.28B |
| High estimate | $1.72B | $1.83B | $6.84B | $7.54B |
| No. of analysts | 16 | 12 | 21 | 22 |
| Year-ago revenue | $1.57B | $1.65B | $6.07B | — |
| Growth | +8.9% | +8.9% | +12.3% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Edwards Lifesciences Corporation. Edwards Lifesciences Corporation has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- AORTArtivion, Inc.Medical - Devices$901M
- AVRAnteris Technologies Global Corp.Medical - Devices$556M
- GNGBYGetinge AB (publ)Medical - Devices$6.1B
- ISRGIntuitive Surgical, Inc.Medical - Instruments & Supplies$151.7B
- LIVNLivaNova PLCMedical - Devices$5.1B
- OCPNFOlympus CorporationMedical - Devices$10.6B
- PENPenumbra, Inc.Medical - Devices$12.6B
More Medical - Devices companies
- BIIOBionovate Technologies CorpOTC$775
- BIOBio-Rad Laboratories, Inc.NYSE$9.7B
- BIO-BBio-Rad Laboratories, Inc.NYSE$9.7B
- BJDXBluejay Diagnostics, Inc.NASDAQ$3M
- BMRABiomerica, Inc.NASDAQ$6M
- BRKRBruker CorporationNASDAQ$9.3B
- BRKRPBruker CorporationNASDAQ$9.3B
- BRNHFBroncus Holding CorporationOTC$42M
- BRSFBrain Scientific Inc.OTC$124
- BSXBoston Scientific CorporationNYSE$63.3B
- BTCYBiotricity, Inc.OTC$8M
- BVSBioventus Inc.NASDAQ$716M
ETFs holding Edwards Lifesciences Corporation
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.08%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.07%
- VOVanguard Mid-Cap ETF$103.4B in assets0.51%
- IVViShares Core SP 500 ETF$852.9B in assets0.10%
- IHIiShares US Medical Devices ETF$4.0B in assets5.00%
- BAFEBrown Advisory Flexible Equity ETF$1.7B in assets2.17%
- BLCRiShares Large Cap Core Active ETF$9.8B in assets2.05%
- JGLOJPMorgan Global Select Equity ETF$6.1B in assets1.01%
Largest holders first, then the funds most concentrated in EW.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Edwards Lifesciences Corporation, and how their positions are changing. At a $61.59B market value, institutional positions materially move Edwards Lifesciences Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Edwards Lifesciences Corporation executives and directors. Shares of Edwards Lifesciences Corporation have traded between $65.94 and $87.21 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Edwards Lifesciences Corporation. Edwards Lifesciences Corporation is a $61.59B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Edwards Lifesciences Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Edwards Lifesciences Corporation. Coverage tracks Edwards Lifesciences Corporation within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Edwards Lifesciences Corporation.